Skip to content

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

Role of Neurotrophic Keratitis Versus Severity of Tear Film and Ocular Surface Parameters in Determining the Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06364657
Acronym
IIR
Enrollment
13
Registered
2024-04-15
Start date
2024-07-01
Completion date
2024-12-19
Last updated
2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis

Keywords

Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis

Brief summary

In this study the investigators plan to enroll three groups of patients: non-Sjogren's dry eye, Sjogren's dry eye and controls. The study has the following primary goals: 1. To determine whether dry eye is associated with reduced corneal sensation 2. To determine whether reduced corneal sensation is due to the severity of the dry eye, the type of dry eye (primarily aqueous deficient versus primarily evaporative) or entirely related to the presence of Sjogren's 3. To determine whether corneal sensation is associated with ocular or systemic pain symptoms Additionally, the study aims to compare the novel corneal esthesiometer measurements to confocal biomicroscopy findings in determining neurotrophic keratitis (NK) and assess correlations between corneal sensation.

Interventions

DIAGNOSTIC_TESTEye Exam

* Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS) * Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey * Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test. * Corneal esthesiometer for measurement of corneal sensation * Schirmer's without topical anesthesia * Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT) * Staining for dry eye: * Tear film break-up time (BUT) using fluorescein. * Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS)) * Lissamine green staining (OSS and Oxford) * Non-contact confocal biomicroscopy for morphology of the ocular surface

Sponsors

Dompe U.S. Inc
CollaboratorUNKNOWN
Johns Hopkins University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female aged 18 or older * Capacity to give informed consent * Self-reported literacy * Best corrected visual acuity at distance 20/40 in each eye * Signed Institutional Review Board (IRB)-approved consent agreeing to the terms of the study For Sjogren's-related dry eye, the below inclusion criteria will be required * a previous diagnosis of dry eye made by an eye care specialist * a previous diagnosis of Sjogren's made according to the 2016 revised Sjogren's classification criteria

Exclusion criteria

* ● Age less than 18 years * Physical or mental issues, illiteracy, or language problems that might possibly interfere with reading ability or other condition that would preclude successful participation in this study * Contact lens wear within 10 days of enrollment * Any intraocular surgery (including cataract surgery) within the last 3 months * Any minor ocular surgery including tear duct cauterization or plugs within the last 30 days * Any history of corneal surgery (including LASIK/PRK) or cosmetic lid surgery in the past 12 months * Any history of glaucoma surgery (e.g., trabeculectomy or a tube shunt) * Best corrected vision worse than 20/40 * Known history of severe ocular surface disease that might cause corneal haze and interfere with corneal staining score including but not limited to graft-versus-host disease, mucous membrane pemphigoid, atopic keratoconjunctivitis * Presence of keratoconus * Concurrent epithelial corneal disease or dystrophy (e.g., anterior basement membrane disease, pterygium, or scarring) that might affect the corneal staining score * Previous use of OXERVATE® for neurotrophic keratitis * Neurotrophic keratoconjunctivitis or corneal/conjunctival scarring (history of herpes simplex virus or varicella zoster virus keratitis) * Any blepharitis eyelid procedures such as Intense Pulsed Light (IPL), low level light treatment therapy, LipiFlow®, or nasolacrimal duct probing in the last 30 days prior to the study visit * Any acupuncture or physical therapy on the face or head within the past 3 months * Current smoker (within the past year) * Pregnant or nursing * Artificial tear use within 2 hours of study visit * Topical ophthalmic non-steroidal anti-inflammatory drug use 24 hours before the study visit * History of taking or current use of topical glaucoma drops or neurostimulation drugs or devices for treating dry eye * History or current intravitreal injections for macular degeneration * History of continuous positive airway pressure usage in the past 3 months * Any concurrent medical condition that in the judgment of the PI might interfere with the conduct of the study, confound the interpretation of the study results.

Design outcomes

Primary

MeasureTime frameDescription
Corneal Epithelium health1 DayMeasuring epithelial staining score and epithelial thickness map using anterior segment Optical coherence tomography (OCT)
Corneal Nerve health1 DayCorneal sensation using non-contact esthesiometer and corneal nerve density and morphology using non-contact confocal biomicroscopy

Secondary

MeasureTime frameDescription
Correlations Between Corneal Staining Score1 DayCorrelations between corneal staining score with visual parameters, epithelial thickness map, corneal nerve density and morphology, and corneal sensation
Correlations Between Patient Symptoms1 DayCorrelations between the patient symptoms and above corneal findings using Ocular Surface Disease Index (OSDI), Visual Acuity Scale (VAS), and pain scale questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026